Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Other Non-Current Assets (2021 - 2026)

Inhibikase Therapeutics (IKT) has 3 years of Other Non-Current Assets data on record, last reported at $1.0 million in Q1 2026.

  • On a quarterly basis, Other Non-Current Assets changed N/A to $1.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.0 million, a N/A change, with the full-year FY2025 number at $1.0 million, changed N/A from a year prior.
  • Other Non-Current Assets reached $1.0 million in Q1 2026 per IKT's latest filing, roughly flat from $1.0 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for IKT hit a ceiling of $1.0 million in Q3 2025 and a floor of $1.0 million in Q3 2025.